Agenda

MASTERCLASS WORKSHOPS
Monday, 4 March 2019
CONFERENCE DAY 1
Tuesday, 5 March 2019
CONFERENCE DAY 2
Wednesday, 6 March 2019

Registration & Light Networking Breakfast

Developing Your Competitive Expertise: Late-Lifecyle Management & Competitive Uncertainty

Dr. Harshal Kubavat, Head, Strategic Consulting, Life Sciences, INOVIS
Baljit Singh, Ph.D., Managing Director and Partner, Global Pharmaceuticals & Life Sciences Division, INOVIS

This workshop session (with breakouts), will give participants first-hand insights from combined 30+ years of experience dealing with uncertainty and helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets.

PART A: Dealing with uncertainty – Developing robust competitive assumptions with a systematic framework (Comp-ACT)

* Demonstrate the importance of comprehensive & robust threat assessments and the impacts these can have on strategic decision making (commercial readiness, development programs, BD opportunities, forecasting, scenario planning, mitigation plans, etc.)

* Provide attendees insights of a systematic framework-driven process to evaluate competitive threats from in-class/out-class competitor assets, which will ultimately ensure proactive and strategic impact

PART B: Late Lifecycle Management – Gx/Biosimilar Issues, Intelligence Options, and Actions

This interactive workshop session will enable you to:

* Set up a best-in-industry Gx/biosimilar RI and CI tracking program

* Understand Gx / Biosimilar product development and entry strategies

* Identify potential regulatory and legal actions to optimize launches in emerging markets and enforce IPR / exclusivity

Presented by Inovis

Networking Lunch

Best Practices to Create/Write Effective and Impactful CI Reports and Presentations

David Alderman, President, Molekule Consulting

An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Presented by Molekule Consulting

Networking Break and Refreshments

Scenario Planning in EMS: How to Build Resilience to the External Environment into the Strategic Plans of Your Decision-Makers

Martina Bozadzhieva, Managing Director, Head of Research, DuckerFrontier
Elizabeth Gorski, Director, Head of EMEA Client Services, DuckerFrontier

The nature of the competitive threat in healthcare originating from EMS: the types of local competitors and how you can compete against them.

Emerging markets governments have considerable potential to disrupt competitive dynamics for multinational pharma players, for example by restricting market access, imposing pricing pressures, and directly supporting local competitors. As CI professionals look to support business leaders and build scenarios around competitive dynamics, they need to take into account what could cause governments to prioritize or accelerate such policies, and how that could disrupt assumptions about the competitive landscape.

In this session, DuckerFrontier will share observations about drivers of these government policies in 2019 across key emerging markets. We’ll then discuss as a group what signposts businesses should monitor to understand why governments may pursue these policies in the first place and what kind of macro factors could lead to changes in government behavior towards the local competitive landscape in pharma on the basis of real-life examples across emerging markets. We’ll then work in breakout groups to build out leading indicators of government action into scenarios about the competitive landscape and communicating these effectively to inform business leaders.

Presented by DuckerFrontier

Masterclasses/Workshops Conclude

Good Morning! Registration & Light Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Presented by Chiesi Farmaceutici S.p.A. and MSD

Keynote: Future of Pharma in the Era of Big Data and AI

Presented by IBM Watson Health

Keynote: Quintessential Agency Industry Partnership – How to Make it Work!

We will role-play what a good and a more difficult agency / client relationship looks like.

The goal of our “performance” is to provide the audience with an entertaining learning experience.

Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results
The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Chiesi Farmaceutici S.p.A. and Molekule Consulting

Refresh & Connect in Exhibition Hall

Keynote: Executive Level Boardroom Discussions

Presented by Chiesi Farmaceutici S.p.A., Debiopharm S.A., Helsinn Healthcare, MSD, Novo Nordisk A/S, Philips Healthcare, Sanofi, and Vifor Pharma

“Ask the Experts” Interactive Breakout Groups: Choose 1 of 5, and these plus more breakout groups will be presented again later this afternoon

(Explore and capture the power of participants’ insights and experiences. Delve into these topics in this fun and informal environment in intimate groups.)
BREAKOUT 1
CI on Generics
While a lot of CI activities and vendor offerings are traditionally tailored towards originator CI, in this roundtable we want to have a look at the generics sector of our industry. Topics to exchange on include differences between originator and generics CI, the typical questions for CI in the generics sector.

Presented by Sandoz

BREAKOUT 2
Competitive Intelligence in the Pharma Emerging Markets: Challenges and Opportunities

With the lack of reliable competitive data in some pharma emerging markets, pharma companies risk making the wrong decisions and launch plans.

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

Presented by Acino International AG

BREAKOUT 3
Growth Journey of a CI Professional - Sharing and Exchanging Experiences and Insights: from Functional to Corporate in Scope, from Ad Hoc to Defined

In this breakout session, Vivian will share some highlights, lessons and insights as a CI professional,

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

Presented by Elanco

BREAKOUT 4
Importance of Patient Adherence for the Healthcare Players

- the place of patient adherence within the pharmaceutical industry decisions

– measuring patient adherence
– the benefits of more communication about patient adherence

Presented by Unither Pharmaceuticals

BREAKOUT 5
How to Calculate the Return of Investment (ROI) for CI? Is It Even Possible?

• The group will discuss what can be measured when analyzing the impact of CI and the Return of Investment (ROI) for CI.

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

Presented by Molekule Consulting

Networking Luncheon

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Using CI to Predict Approval Timelines

• With the various designations that the FDA grants new therapies, how can we use CI to predict approval timelines?

o Overview of Phase 3 to approval timelines
o Summary of FDA programs to expedite development of new therapies and how they can impact approval timelines
o Using competitive intelligence to inform approval timelines

Presented by Lifescience Dynamics

SESSION TWO

Dealing with Uncertainty – Experiences, Challenges and Opportunities

Within the Pharma industry, Competitive Intelligence is becoming established as providing vital support in enabling strategy and decision making at a cross-functional level.

However, with increasing complexities surrounding competitive assumptions and the opportunities/challenges they impact within a global environment, many CI professionals find it increasingly difficult to move beyond the “information” provider to “thought-partner” for their stakeholders. At INOVIS, we are progressively dealing with clients struggling to deal with the unknown, with the fear of uncertainty greatly contributing to a lack of agility and competitive fitness across organizations.

Join us for a co-presentation with a leading industry expert and INOVIS as we explore these topics and discuss:
 Real-world examples from Pharma professionals, where overarching uncertainties have impacted business issues
– How was uncertainty addressed?
– What are the learnings?
 How can CI – be it a mindset or specific framework(s) – generate actionable and tangible outcomes to support the current pharma business environment?
 What are the opportunities for high-impact/high value vendor-client activities to better support this area?

Participants will benefit from the vast experience of the presenters and take home ideas and practical considerations to immediately implement as part of their working practices. Moreover, by strengthening and leveraging their client relationships, drawing on specific expertise and experience, CI professionals should leave with more confidence in dealing with the unknown and turning these challenging situations to their opportunity!

Presented by Inovis and Jazz Pharmaceuticals

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Beyond Competitive Intelligence - The ONE Thing You Can Do To Have More Impact And Get A Promotion

There's this little-known thing called Exponential Advantage. Hardly anybody is talking about it. But when you learn it and use it, you'll see a huge impact on your organization and how fast you can get a promotion. The objectives of this presentation are:

• Discover new sources of human intelligence
• Get you more visibility with senior management
• Help you get a promotion

Presented by Atacana Group

SESSION TWO

Personalized Healthcare - Driving the Pharma/IT Convergence

Personalized medicine is a reality but still represents a paradigm shift for the pharmaceutical industry and is forcing the convergence between pharma and information technology.

Pharmaceutical companies need access to a wide range of reliable, relevant data helping them to rapidly assess the best path forward for a particular project, trial design, commercial launch strategy, product differentiation or reimbursement negotiation in order to achieve the optimal outcome. New technologies are impacting this evolving landscape in the shape of companion diagnostics and convenient wearables devices, thereby not only making the collection of data important but also emphasizing that analysis of these collected data through the right technology is critical. Uptake and acceptance of expensive new therapies is enhanced if significant benefit to a particular patient segment can be demonstrated, resulting in the need for data granularity and an ability to filter large datasets with a deep background understanding of the disease and patient.

Prescient will address the challenges companies are facing and the increasing demands for predictive analysis.

Presented by Prescient Healthcare Group

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Transformative Innovation - How ‘Big Pharma’ Is Seeking to Replicate the Creativity and Nimbleness of ‘Start-Up Pharma’?

• Ambition horizons and investment in transformative growth

• “Design Thinking” and its application across the whole organisation
• Digital transformation and the rise of the Chief Digital Officer

Presented by Dig Worldwide

SESSION TWO

I Love My Boss, Do I Need a Psycologist?

When we consider bringing out the best of our team members, we mainly work on improving their skills, knowledge and abilities.

However, as leaders, how much time and effort do we invest in creating the optimal working atmosphere where the happiness becomes the fuel that keeps the motivation running?

Presented by Merz

Refuel & Rejuvenate in Exhibition Hall

“Ask the Experts” Interactive Breakout Groups: Choose 1 of 5

(Explore and capture the power of participants’ insights and experiences. Delve into these topics in this fun and informal environment in intimate groups.)
BREAKOUT 1
How to Construct Business Case – What to Not Forget

Presented by SOTIO, a.s.

BREAKOUT 2
How to Calculate the Return of Investment (ROI) for CI? Is It Even Possible?

• The group will discuss what can be measured when analyzing the impact of CI and the Return of Investment (ROI) for CI.

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

Presented by Molekule Consulting

BREAKOUT 3
CI on Generics
While a lot of CI activities and vendor offerings are traditionally tailored towards originator CI, in this roundtable we want to have a look at the generics sector of our industry. Topics to exchange on include differences between originator and generics CI, the typical questions for CI in the generics sector.

Presented by Sandoz

BREAKOUT 4
Importance of Patient Adherence for the Healthcare Players

- the place of patient adherence within the pharmaceutical industry decisions

– measuring patient adherence
– the benefits of more communication about patient adherence

Presented by Unither Pharmaceuticals

BREAKOUT 5
Increasing FTEs without Increasing FTEs: How to Expand CI Activities within the Company

Presented by Chiesi Farmaceutici S.p.A.

“Ask the Experts” Interactive Breakout Groups: Choose 1 of 5

(Explore and capture the power of participants’ insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
Increasing FTEs without Increasing FTEs: How to Expand CI Activities within the Company

Presented by Chiesi Farmaceutici S.p.A.

BREAKOUT 2
Growth Journey of a CI Professional - Sharing and Exchanging Experiences and Insights: from Functional to Corporate in Scope, from Ad Hoc to Defined

In this breakout session, Vivian will share some highlights, lessons and insights as a CI professional,

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

Presented by Elanco

BREAKOUT 3
Competitive Intelligence in the Pharma Emerging Markets: Challenges and Opportunities

With the lack of reliable competitive data in some pharma emerging markets, pharma companies risk making the wrong decisions and launch plans.

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

Presented by Acino International AG

BREAKOUT 4
How to Construct Business Case – What to Not Forget

Presented by SOTIO, a.s.

BREAKOUT 5
Do you Believe in Life after CI? Career Moves for CI Practitioners

Presented by Swiss eSports Federation/Tribe Gaming

Cocktail Reception and Networking (Drinks Sponsored by Springer Nature)

Good Morning! Registration & Light Networking Breakfast in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Decoding Signals of Development and Disruption

I’ll talk about how with so much tech noise in healthcare going in on now; how teams can spot real trends that lead to disruption and not lose track or derail the strategy due to ‘disruptive’ but otherwise isolated innovation.

Presented by Abbott Established Pharmaceuticals

SESSION TWO

How CI Can Support Strategic Planning

Competitive Intelligence is a critical process in both the short and long term Strategic Planning, providing inputs for the different scenarios build up in the Pharmaceutical and Biotech industry.

Presented by TESARO

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

The Asset Journey: Optimizing Tools and Personnel to Maximize ROI from CI Throughout

Making regulatory predictions is highly dependent on a myriad of variables throughout the lifecycle of drug development, otherwise known as the asset journey.

From basic research to preclinical R&D to FIH and registrational trials to filing and approval and eventual lifecycle management, each step of the asset journey has unique challenges, questions, indicators, and levers that can be used to predict eventual impact on a given therapeutic landscape. Proactive Worldwide will give an overview of strategies, tools, and ideal personnel to address each of these unique steps in the asset journey. Applying the proper mix of skilled researchers, analysts, and appropriate tools will allow for maximum ROI when conducting competitive monitoring in the pharmaceutical development space, irrespective of therapeutic area.

Presented by Proactive Worldwide

SESSION TWO

Partnering 100: Key Insights from the Last 100 Deals in BioPharmaceutical Industry

This presentation aims to deliver a few insights to both the sell-side and buy-side CI professionals. Following will be covered

— Trend analysis of different partnering formats (in/out-licensing, Mergers/Acquisitions, R&D Collaborations, Co-Dev/Co-Mktg. alliances) by TA, development stage, valuation etc.
— Identify the top 3-5 deals from the partnering landscape and the underlying strategic drivers
— The most successful deal makers and what makes them so
— Future Outlook: Is the frenzy likely to continue?

Presented by RAS LSS Consulting

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

The Challenge of Uncertain Futures – Integrating CI into Strategic Decision Making

Over a number of years Osprey Health Consulting has recognised the growing challenge facing the CI professional community in defining

the implications of CI in markets where there are multiple possible futures and where uncertainty is increasing. The Osprey Health Consulting presentation will highlight the reasons for increasing uncertainty about the future of markets and how this challenges strategic decision making in pharma. How CI professionals can adapt to this new world to ensure the information they provide facilitates improved decision making will be discussed. The critical role of CI in informing, supporting and validating strategic decision making in real-time assessments of markets will be explored and models of how this can be achieved will be proposed.

Presented by Osprey Health Consulting

SESSION TWO

What to Consider When Setting up the Company’s CI Function?

• Deciding on the ambition level

• Leveraging your internal network
• External partners – how to go about it?

Presented by Leo Pharma

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Knowledge Management

Like AI and ML, Knowledge Management has made it back on the pharma stage.

While its precise meaning is open for discussion (and in which field is that not the case), the focus on knowledge and insights, versus managing systems and data, has made it a powerful point of view to address real world challenges in the life science / pharma space. At Roche, for example, several large KM projects have been initiated, that look beyond IT to optimise and structure the information flow across functions and sites. The use of Machine Learning is a tool to improve the quality of the information, and various semantic data integration topics help to identify the insights our R&D colleagues are looking for.

Presented by Roche

SESSION TWO

D-I-Y CSW – Potential Low Cost Option For CI to Drive Action But Does It Bring the Goods?

As pressure to deliver CI in a more cost-effective way often amounts on CI professionals’ shoulders during the

objective/budget setting times, Do-It-Yourself Competitive Strategic Workshops (D-I-Y CSW) may sound like a tempting CI approach to offer to cost conscious stakeholders. This no-slides presentation will share personal lessons learned about setting up and executing D-I-Y CSWs, including, on balance, some reflection on agency-driven CSWs

Presented by Bayer

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Systems Thinking in Decision Making

The success of a CI professional in any company is critically dependent on one’s ability to influence decisions.

Inability to convince one’s stakeholders to make a different decision based on the competitive situation can lead to mistakes of judgement and ultimately end in failure for an inline or pipeline asset. In order to better understand how to influence executive decisions, one needs to understand the decision-making journey and systems of thinking. In this presentation, we shall explore the two main systems of thinking, mental heuristics, and strategies for eliciting the right responses when communicating with decision-makers.

Presented by MSD

SESSION TWO

Decision Making Based on Stochastic Simulation of Drug Development Process

As the services a CMO can provide to the pharma and biotech industry vary according to the lifecycle stage a

molecule is currently found, it becomes crucial to predict the future state of the pharma and biotech projects’ pipeline. Stochastic simulation can be applied to understand the dynamics of the drug development process and to assess how likely certain states are expected to materialize, and such outcomes drive decision making across several business processes at Lonza.

Presented by Lonza

Networking Luncheon

Announcements

Panel Discussion: New Products and Launch Strategy

Presented by Bayer, Fresenius Kabi, Jazz Pharmaceuticals, Swiss eSports Federation/Tribe Gaming

Livepolling Power Panel: Review and Discussion of the Most Controversial and Important Topics Over the Two Days

Presented by Chiesi Farmaceutici S.p.A., Debiopharm S.A., Helsinn Healthcare, MSD, Novo Nordisk A/S, Philips Healthcare, Sanofi, and Vifor Pharma

Chairpersons’ Closing Remarks

Presented by MSD and Vifor Pharma

Conference Concludes